Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival

CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934

Source: Clinical Lung Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research